Kodiak Sciences (KOD) Total Non-Current Liabilities (2017 - 2026)
Kodiak Sciences (KOD) reported Total Non-Current Liabilities of $93.9 million for Q1 2026, up 5.43% on a YoY basis from $89.1 million in Q1 2025, and little changed quarter-over-quarter from $94.1 million in Q4 2025.
Kodiak Sciences (KOD) Total Non-Current Liabilities (2017 - 2026) Analysis & Trends
Kodiak Sciences has reported Total Non-Current Liabilities for 10 years, with the latest figure at $93.9 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities rose 5.43% year-over-year to $93.9 million; the trailing twelve-month figure through Mar 2026 stood at $93.9 million (up 5.43% YoY), and the FY2025 full-year result was $94.1 million, up 10.39% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $93.9 million, roughly flat from $94.1 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $251.2 million in Q2 2023, with the low at $85.3 million in Q4 2024.
- Historically, Total Non-Current Liabilities has averaged $132.2 million across 5 years, with a median of $94.4 million in 2025.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities jumped 85.12% — and 2024, when it slumped 65.33%.
- Kodiak Sciences' Total Non-Current Liabilities stood at $230.3 million in 2022, then sank by 50.68% to $113.6 million in 2023, then slipped by 24.91% to $85.3 million in 2024, then grew by 10.39% to $94.1 million in 2025, then fell by 0.26% to $93.9 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $93.9 million (Q1 2026), $94.1 million (Q4 2025), and $94.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 42,980.09 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 64.76 Mn |
| 10 | Kodiak Sciences | 1.95 Bn | 1.95 Bn | - | 93.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 93.91 Mn |
| Dec 31, 2025 | 94.15 Mn |
| Sep 30, 2025 | 94.38 Mn |
| Jun 30, 2025 | 86.44 Mn |
| Mar 31, 2025 | 89.07 Mn |
| Dec 31, 2024 | 85.29 Mn |
| Sep 30, 2024 | 87.30 Mn |
| Jun 30, 2024 | 87.07 Mn |
| Mar 31, 2024 | 93.57 Mn |
| Dec 31, 2023 | 113.59 Mn |
| Sep 30, 2023 | 145.24 Mn |
| Jun 30, 2023 | 251.18 Mn |
| Mar 31, 2023 | 147.75 Mn |
| Dec 31, 2022 | 230.30 Mn |
| Sep 30, 2022 | 244.28 Mn |
| Jun 30, 2022 | 151.01 Mn |
| Mar 31, 2022 | 152.95 Mn |
| Dec 31, 2021 | 240.69 Mn |
| Sep 30, 2021 | 131.96 Mn |
| Jun 30, 2021 | 118.26 Mn |